Macular Degeneration Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Macular Degeneration stocks.

Macular Degeneration Stocks Recent News

Date Stock Title
Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 GILD 5 FDA decisions to watch in the third quarter
Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
Jul 2 REGN Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Jul 2 REGN Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
Jul 2 GILD Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
Jul 2 GILD Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
Jul 1 REGN Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Jul 1 GILD Gilead Benefit Helps Employees Navigate Cancer Care
Jul 1 BNTC Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
Jul 1 GILD Should You Hold Gilead Sciences (GILD)?
Jul 1 GILD 3 Magnificent Stocks Retirees Can Buy and Hold Forever
Jun 29 CRVO CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans
Jun 28 REGN What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Jun 28 REGN Regeneron lymphoma antibody drug endorsed for conditional approval in EU
Jun 28 REGN Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Jun 27 REGN Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Jun 27 ALIM Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Macular Degeneration

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

Browse All Tags